Antihistamines in late-phase clinical development for allergic disease

Bibliography

• BECKMAN DB, GRAMMER LC: Pharmacotherapy to prevent the complications of allergic rhinitis. Allergy Asthma Proc. (1999) 20:215–223.
   PubMed Web of Science ®Google Scholar
• DYKEWICZ MS, FINEMAN S, SKONER DP et al: Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann. Allergy Asthma Immurrol (1998) 81:478–518.
   PubMed Web of Science ®Google Scholar
• •Extensive documentation of guidelines for the diagnosis and treatment of patients with allergic and non-allergic rhinitis.
   Google Scholar
• LUNDBACK B: Epidemiology of rhinitis and asthma. Clirr. Exp. Allergy (1998) 28:3–10.
   PubMed Web of Science ®Google Scholar
• SPECTOR SL: Overview of comorbid associations of allergic rhinitis. j Allergy Clirr. Immurrol (1997) 99:S773–S780.
   PubMed Web of Science ®Google Scholar
• CORREN J: The impact of allergic rhinitis on bronchial asthma. j Allergy Clirr. Immurrol (1998) 101(2 pt 2):S352–S356.
   Google Scholar
• ••AR may predispose patients to asthma, andtreatment of AR may improve asthmatic symptoms.
   Google Scholar
• RACHELEFSKY GS: National guidelines needed to manage rhinitis and prevent complications. Ann. Allergy Asthma Immurrol (1999) 82:296–305.
   PubMed Web of Science ®Google Scholar
• SABROE RA, GREAVES MW: The pathogenesis of chronic idiopathic urticaria. Arch. Dermatol. (1997) 133:1003–1008.
   PubMed Web of Science ®Google Scholar
• RING J, HEIN R, GAUGER A: Desloratadine in the treatment of chronic idiopathic urticaria. Allergy (2001) 56\(Suppl. 65):28–32.
   Google Scholar
• BOUSQUET J, VAN CAUWENBERGE P, KHALTIEV N: Allergic rhinitis and its impact on asthma. Executive summary, World Health Organization (2000):2–32..
   Google Scholar
• DUBUSKE LM: Clinical comparison of histamine H1-receptor antagonist drugs. Allergy Clirr. Immurrol (1996) 98(6 pt 3):S307–S318.
   Google Scholar
• MANN RD, PEARCE GL, DUNN N, SHAKIR S: Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. Br. Med. J. (2000) 320:1184–1186.
   PubMed Web of Science ®Google Scholar
• HORAK F, STUBNER UP: Comparative tolerability of second-generation antihistamines. Drug Sal: (1999) 20:385–401.
   PubMed Web of Science ®Google Scholar
• ••Excellent comparative overview of second- generation antihistamines with regard to improved CNS side effects and cardiotmdcity.
   Google Scholar
• MOSS AJ, CHAIKIN P, GARCIA JD et al: A review of the cardiac systemic side effects of antihistamines: ebastine. Clirr. Exp. Allergy (1999) 29\(Suppl. 3):200–205.
   Google Scholar
• MICHALETS EL: Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy (1998) 18:84–112.
   PubMed Web of Science ®Google Scholar
• PEARLMAN DS: Pathophysiology of the inflammatory response. j Allergy Clirr. Immurrol (1999) 104:S132–S137.
   PubMed Web of Science ®Google Scholar
• ••Critical and extensive review of theinflammatory mediators of early- and late-phase allergic inflammation.
   Google Scholar
• NACLERIO RIVI: Allergic rhinitis. N Engl. Med. (1991) 325:860–869.
   PubMed Web of Science ®Google Scholar
• WILLS-KARP M: Immunologic basis of antigen-induced airway hyperresponsiveness. Ann. Rev Immurrol (1999) 17:255–281.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive evaluation of the role ofcytokines and cellular components in allergic disease; relates the contribution of TH2-specific cytokines to the immune response, inflammation, and bronchial hyper-reactivity.
   Google Scholar
• KAY AB: Allergy and allergic diseases. First of two parts. N Engl. j Med. (2001) 344:30–37.
   PubMed Web of Science ®Google Scholar
• TOGIAS AJ: Unique mechanistic features of allergic rhinitis. I Allergy Clirr. Immurrol (2000) 105:S599–S604.
   PubMed Web of Science ®Google Scholar
• ••Describes the impact of AR on asthma -emphasis on humoral mediators and their interaction with neural pathways in the pathogenesis of allergic disease.
   Google Scholar
• MOSIMANN BL, WHITE MV, HOHMAN RJ et al: Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. Allergy Clirr. Immurrol (1993) 92:95–104.
   PubMed Web of Science ®Google Scholar
• MOLET S, GOSSET P, LASSALLE P etal.: Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clirr. Exp. Allergy (1997) 27:1167–1174.
   Google Scholar
• FRIGAS E, MOTOJIMA S, GLEICH GJ: The eosinophilic injury to the mucosa of the airways in the pathogenesis of bronchial asthma. Eur. Respir. J. (1991) 13(Suppl):123s–135s.
   Google Scholar
• HOLGATE ST: Asthma: a dynamic disease of inflammation and repair. Ciba Found. Symp. (1997) 206:106–110.
   Google Scholar
• HERBERT CA, ARTHUR MJ, ROBINSON C: Augmentation by eosinophils of gelatinase activity in the airway mucosa: comparative effects as a putative mediator of epithelial injury. Br. Pharmacol (1996) 117:667–674.
   PubMed Web of Science ®Google Scholar
• WALSH GM, ANNUNZIATO L, FROSSARD N et al.: New insights into the second-generation antihistamines. Drugs (2001) 61:207–236.
   PubMed Web of Science ®Google Scholar
• ••Thorough critical assessment of the "old"first-generation and "new" second-generation antihistamines with respect to pharmacokinetics, toxicity, and efficacy in allergic disease.
   Google Scholar
• HADLEY JA: Evaluation and management of allergic rhinitis. Med. Clirr. North Am. (1999) 83:13–25.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of diagnosis andtreatment of AR, with emphasis on antihistamines.
   Google Scholar
• GONZALEZ MA, ESTES KS: Pharmacokinetic overview of oral second-generation H1 antihistamines. Int. I Clirr. Pharmacol Ther. (1998) 36:292–300.
   PubMed Web of Science ®Google Scholar
• Astelin (azelastine hydrochloride) prescribing information. Wallace Laboratories, ASTA Medica LLC, April 2000.
   Google Scholar
• CVETKOVIC M, LEAKE B, FROMM MF et al.: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. (1999) 27:866–871.
   PubMed Web of Science ®Google Scholar
• ••Metabolic pathways independent of thecytochrome P450 system compromise the pharmacokinetics of certain antihistamines.
   Google Scholar
• TABORDA-BARATA L, JACOBSON M, WALKER S etal.: Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clirr. Exp. Allergy (1996) 26:68–78.
   Google Scholar
• ZWEIMAN B, ATKINS PC, MOSKOVITZ A et al.: Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. j Allergy Clirr. Immurrol (1997) 100:341–347.
   PubMed Web of Science ®Google Scholar
• ATKINS PC, ZWEIMAN B, MOSKOVITZ A et al.: Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine. j Allergy Clirr. Immurrol (1997) 99:806–811.
   PubMed Web of Science ®Google Scholar
• ••
   Google Scholar
• AGRAWAL DK: Pharmacology and clinical efficacy of desloratadine as an antiallergic and anti-inflammatory drug. Expert Opin. Imestig. Drugs (2001) 10:547–560.
   PubMed Web of Science ®Google Scholar
• ••Extensive evaluation of the pro-inflammatory, anti-allergic and unique decongestant properties of desloratadine; provides a critical evaluation of the safety of desloratadine for treating patients with allergic disease.
   Google Scholar
• GEHA RS, MELTZER EO: Desloratadine: a new, non-sedating antihistamine. I Allergy brunurrel. (2001) 107:751–762.
   Google Scholar
• ••Extensive critical review of the preclinicalpharmacology, pharmacokinetics, metabolism and clinical efficacy and safety of desloratadine.
   Google Scholar
• KREUTNER W, HEY JA, ANTHES J et al: Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1-antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneirnittelferschung (2000) 50:345–352.
   Google Scholar
• GENOVESE A, PATELLA V, DE CRESCENZO G et al.: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clirr. Exp. Allergy (1997) 27:559–567.
   Google Scholar
• MELTZER E, PRENNER B, NAYAK A et al.: Desloratadine study group. Efficacy and safety of once-daily 5 mg desloratadine, a potent histamine H1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons. Clirr. Drug Invest. (2001) 21:25–32.
   Google Scholar
• DALY AF: Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetirizine, and loratadine Allergy (2001) 56\(Suppl. 68):79.
   Google Scholar
• ••Desloratadine exhibits more potentdecongestant activity than other second-generation antihistamines in patients with SAR.
   Google Scholar
• HORAK F, STUBNER P, ZIGLMAYER R et al.: Decongestant activity of desloratadine versus placebo in allergic rhinitis: results from three single-dose, placebo-controlled allergen chamber trials. Allergy (2001) 56\(Suppl. 68):79.
   Google Scholar
• ••Describes the unique decongestant activityof desloratadine in patients with AR.
   Google Scholar
• HORAK E STUBNER UP, ZIEGLMAYER R etal.: Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis. Allergy (2000) 55 (Suppl. 63):279.
   Google Scholar
• DUBUSKE LM: Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks. I Allergy Clirr. Immune] (2001) 107(2):S159.
   Web of Science ®Google Scholar
• LORBER R, DANZIG M: Desloratadine and pseudophedrine provide similar relief of nasal congestion in patients with seasonal allergic rhinitis. Poster presented at the XXth Congress of the European Academy of Allergology and Clinical Immunology, Berlin, Germany, May 9–13, 2001. Poster 905.
   Google Scholar
• BAENA-CAGNANI C: Desloratadine improved asthma symptoms and decreased beta2-agonist use in patients with seasonal allergic rhinitis and concomitant asthma. Allergy (2001) 56\(Suppl. 68);22–23.
   Google Scholar
• ••Describes the unique anti-allergic effects ofdesloratadine in patients with SAR and concomitant asthma, including a sparing effect on the use of bronchodilators.
   Google Scholar
• BERGER WE: Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma. I Allergy CM. brunurrel. (2001) 107(2):S162.
   Web of Science ®Google Scholar
• SHAPIRO GG: Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma. I Allergy Clirr. Immune] (2001) 107(2):S161.
   Web of Science ®Google Scholar
• RATNER PH: Long-term benefit of desloratadine against seasonal allergic rhinitis symptoms in patients with asthma. I Allergy Clirr. Irrenurrel (2001) 107(2):S161.
   Web of Science ®Google Scholar
• RING J, HEIN R, GAUGER A et al: Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Int. I Dermatel. (2001) 40:72–76.
   PubMed Web of Science ®Google Scholar
• KREUTNER W, HEY JA, CHIU P et al:Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Armeirnittelferschung (2000) 50:441–448.
   Google Scholar
• VALK PJL, VAN ROON DB, SIMONS M etal.: No impairment of flying ability with desloratadine use in healthy volunteers under conditions of simulated cabin pressure. Allergy (2001) 56\(Suppl. 68):78–79.
   Google Scholar
• •Emphasises desloratadine safety with respect to lack of CNS sedation and psychomotor side effects.
   Google Scholar
• BANFIELD C, CAYEN M, GUPTA S et al: Grapefruit juice has no effect on the bioavailability of desloratadine but reduces the C and AUC of fexofenadine by 30%. Ann. Allergy Asthma brunurrel. (2001) 86:108.
   Google Scholar
• ••Emphasises the importance of food/druginteractions on antihistamine bioavailability through interaction with the P-glycoprotein transport system.
   Google Scholar
• SIMONS FE: Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Clirr. Exp. Allergy (1999) 29:3–8.
   PubMed Web of Science ®Google Scholar
• LEVRIER J, DUVAL D, PROUTEAU Met al.: Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. Armeirnittelferschung (1995) 45:559–568.
   Google Scholar
• •Describes multiple anti-inflammatory properties of mizolastine, including its dual H1 receptor/PAF antagonist activity.
   Google Scholar
• ROSENZWEIG P, CAPLAIN H, CHAUFOUR S et al: Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br I Clirr. Pharrnacel (1995) 40:459–465.
   PubMed Web of Science ®Google Scholar
• PICHAT P, ANGEL I, ARBILLA S: Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Armeirnittelferschung (1998) 48:173–178.
   PubMed Web of Science ®Google Scholar
• LEYNADIER F, BOUSQUET J, MURRIETA M et al.: Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann. Allergy Asthma Immune] (1996) 76:163–168.
   PubMed Web of Science ®Google Scholar
• •Demonstrates mizolastine's superiority to loratadine in suppressing symptoms of CIU, including angioedema.
   Google Scholar
• BELLIONI P, CATALANO B, CERVELLERA G et al.: Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhirto/ogy (1996) 34:101–104.
   Google Scholar
• BACHERT C, BROSTOFF J, SCADDING GK etal.: Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy (1998) 53:969–975.
   Google Scholar
• SABBAH A, DAELE J, WADE AG et al.: Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. Ann. Allergy Asthma kenurrel. (1999) 83:319–325.
   PubMed Web of Science ®Google Scholar
• •Demonstrates mizolastine's rapid onset of action, and efficacy equivalent to cetirizine in treating SAR.
   Google Scholar
• SCADDING GK, TASMAN AJ, 271 MURRIETA-AGUTTES M et al.: Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis. Riperex Study Group. Int. Med. Res. (1999) 27:273–285.
   Google Scholar
• •Describes the long-term effects of mizolastine on multiple symptoms of SAR.
   Google Scholar
• BROSTOFF J, FITZHARRIS P, DUNMORE C et al: Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy (1996) 51:320–325.
   PubMed Web of Science ®Google Scholar
• DUBERTRET L, MURRIETA AGUTTES M, TONET J: Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. j Eur. Acad. Derrnatal Venereal (1999) 12:16–24.
   PubMed Web of Science ®Google Scholar
• •Mizolastine represents a more effective treatment option for CIU than loratadine.
   Google Scholar
• LEYNADIER F, DUARTE-RISSELIN C, MURRIETA M: Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur. j Dermatal (2000) 10:205–211.
   PubMed Web of Science ®Google Scholar
• LORETTE G, GIANNETTI A, PEREIRA RS et al.: One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group. j Eur. Acad. Derrnatal Venereal (2000) 14:83–90.
   PubMed Web of Science ®Google Scholar
• TAGLIALATELA M, PANNACCIONE A, CASTALDO P et al.: Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br. Pharrnacal. (2000) 131:1081–1088.
   PubMed Web of Science ®Google Scholar
• LEBRUN-VIGNES B, DIQUET B, CHOSIDOW 0: Clinical pharmacokinetics of mizolastine. Clin. Pharrnacakinet. (2001) 40:501–507.
   PubMed Web of Science ®Google Scholar
• •Emphasises mizolastine's potential for multiple drug interactions and altered pharmacoltinetics in patients with renal and hepatic dysfunction.
   Google Scholar
• DEVALIA JL, DE VOS C, HANOTTE F et al.: A randomised, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy (2001) 56:50–57.
   PubMed Web of Science ®Google Scholar
• •Relates cetirizine's anti-allergic activity to the 0-enantiomer levocetirizine, its active metabolite, rather than the (V-enantiomer.
   Google Scholar
• CLOUGH GE BOUTSIOUKI P, CHURCH MK: Comparison of the effects of levocetirizine and loratadine on histamine- induced wheal, flare, and itch in human skin. Allergy (2001) 56:985–988.
   PubMed Web of Science ®Google Scholar
• JAZRAWI E, STIRLING R, CHUNG KF: Effect of levocetirizine on eotaxin-induced eosinophil chemotaxis with and without interlukin-5 priming in vitro. Allergy (2001) 56\(Suppl. 68):138.
   Google Scholar
• THOMSON L, BLAYLOCK MG, WALSH GM: Levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Allergy (2001) 56\(Suppl. 68):123.
   Google Scholar
• WANG DY, HANOTTE E DE VOS C et al.: Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy (2001) 56:339–343.
   Google Scholar
• •Identifies levocetirizine, not dextrocetirizine, as the active metabolite of cetirizine in histamine-induced rhinitis.
   Google Scholar
• HORAK F, STUBNER UP, ZIEGLMAYER R et al: Effect of levocetirizine and loratadine on symptom relief in house-dust mite allergic patients exposed to allergen in the Vienna challenge chamber. Allergy (2001b) 56\(Suppl. 68):201–202.
   Google Scholar
• Xusal (levocetirizine) prescribing information. UCB GmbH. February 2001.
   Google Scholar
• STROLIN-BENEDETTI M, PLISNIER M,KAISE J et al: Absorption, distribution, metabolism and excretion of [14C1-levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Allergy (2001) 56\(Suppl. 68):201.
   Google Scholar
• BALTES E, COUPEZ R, GIEZECK H et al.: Absorption and distribution of levocetirizine, the eutomer of cetirizine, administered alone, or as cetirizine to healthy volunteers. Fundarn. Clirr. Pharrnacal (2001) 15:269–277.
   PubMed Web of Science ®Google Scholar
• BACHMANN KA: Norastemizole Sepracor.Curr. Opirr. Invest. Drugs (2000) 1:219–226.
   PubMedGoogle Scholar
• •Demonstrates ant-allergy potency and safety advantages of norastemizole over astemizole.
   Google Scholar
• HANDLEY DA, HONG Y, BAKALE R et al.: Norastemizole. Antihistamine. Drugs Future (1998) 23:966–969.
   Google Scholar
• FISCHER MJ, PAULUSSEN JJ, DE MOL NJ et al.: Dual effect of the anti-allergic astemizole on Ca2+ fluxes in rat basophilic leukemia (RBL-2H3) cells: release of Ca2+ from intracellular stores and inhibition of Ca2+ release-activated Ca2+ influx. Biachern. Pharrnacal (1998) 55:1255–1262.
   Google Scholar
• DAY JH, BRISCOE MP, RAFEIRO E et al: Norastemizole (NORA) acts earlier and is more effective for allergic rhinitis symptoms than loratadine (LAT) and placebo (PBO) in an allergen challenge. I Allergy CM. kanurial (2000) 104(1 pt 2):5202.
   Google Scholar
• HEY JA, DEL PRADO M, SHERWOOD J et al: Comparative analysis of the cardiotoxicity proclivities of second-generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arznehnittelforschung (1996) 46:153–158.
   PubMed Web of Science ®Google Scholar
• ZHOU Z, VORPERIAN VR, GONG Q et al.: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. j Cardievasc. Electraphysial (1999) 10:836–843.
   PubMed Web of Science ®Google Scholar
• MERLOS M, GIRAL M, BALSA D et al: Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAR j Pharrnacal Exp. Ther. (1997) 280:114–121.
   Google Scholar
• •Describes the pharmacological profile of one of the most potent H1 antagonists in development today; also potential of dual-active H1 R/PAF antagonist for treating allergy.
   Google Scholar
• QUERALT M, BRAZIS P, MERLOS M et al.: In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Irillarran. Res. (2000) 49:355–360.
   Google Scholar
• IZQUIERDO I, LURIGADOS C, PEREZ I et al.: Rupatadine exhibits a better profile than ebastine in patients with seasonal allergic rhinitis. Allergy (2001) 56\(Suppl. 68)200.
   Google Scholar
• CABALLERO R, VALENZUELA C, LONGOBARDO M et al: Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels. Br. J. Pharinacal (1999) 128:1071–1081.
   PubMed Web of Science ®Google Scholar
• IZQUIERDO I, PEREZ I, VILLA M et al: Lack of electrocardiographic effects of rupatadine, a new non-sedating selective histamine H1-receptor and PAF antagonist. Allergy (2001) 56\(Suppl. 68):200–201.
   Google Scholar
• FIREMAN P, TANNER E, CHOUNG J et al.: Effect of topical UCB-28754 on rhinitis provoked by intranasal histamine in the monkey. Allergy Clirr. Irninurial New (1994) Suppl 2:1136.
   Google Scholar
• TANNER E, CHOUNG JT, SVARTS J et al.: Effect of topical UCB-28754 on rhinitis provoked by intranasal histamine and Ascaris suum in the monkey. Am. j. Rhino]. (1996) 10:45–49.
   Google Scholar
• DE VOS C, WNG D-Y, CLEMENT P: Effect of topical UCB-28754 nasal spray on the mucociliary transit time in adult healthy volunteers. Allergy Chi]. Immurrol News (1994) Suppl 2:1496.
   Google Scholar
• DESSANGES J-F, DJABALLAH K, DIN-XUAN AT et al.: Effect of topical UCB-28754 on the histamine nasal provocation test in healthy adult volunteers. Allergy Chi]. Immurrol News (1994) Suppl 2:1864.
   Google Scholar
• PINELLI ME, VERVOLET D: Etletirizine nasal spray dose-ranging study in grass pollen-associated allergic rhinoconjunctivitis. J. Allergy Chi]. Immurrol (1995) 95:229.
   Web of Science ®Google Scholar
• KAKIUCHI M, OHASHI T, MUSOH K et al.: Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn.j Pharmacol (1997) 73:291–298.
   PubMedGoogle Scholar
• MUSOH K, NAKAMURA N, NAGAI H: Effects of an amphoteric antiallergic agent, HSR-609, on antigen-induced late phase nasal eosinophilia in brown Norway rats. Pharmacology (2000) 61:230–237.
   PubMed Web of Science ®Google Scholar
• •HSR-609 is more potent than cetirizine in suppressing eosinophil infiltration in an antigen-induced AR model.
   Google Scholar
• MUSOH K, MAEDA Y, TANAKA H et al: Effect of a novel anti-allergic agent, HSR-609, on antigen-induced airway hyperresponsiveness in mice. Pharmacology (2000) 61:70–77.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the broad-spectrum anti-inflammatory/anti-asthmatic potential of HSR-609 for treatment of allergic disease.
   Google Scholar
• KAKIUCHI M, OHASHI T, TANAKA K et al.: Pharmacological studies on the novel antiallergic agent HSR-609: its effects on behavior in mice and electroencephalograms in rabbits. Jpn.j Pharmacol (1997) 75:43–57.
   PubMedGoogle Scholar
• GRANT JA, DANIELSON L, RIHOUX JPet al.: A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy (1999) 54:700–707.
   Google Scholar
• FUKUISHI N, KAN T, HIROSE K et al.:Inhibitory effect of epinastine on superoxide generation by rat neutrophils. Jpri. Pharmacol (1995) 68:449–452.
   PubMedGoogle Scholar
• KOHYAMA T, TAKIZAWA H, AKIYAMA N et al: A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem. Biophys. Res. Commun. (1997) 230:125–128.
   PubMed Web of Science ®Google Scholar
• MITA H, SHIDA T: Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes. Arzneimittelforschung (1995) 45:36–40.
   PubMed Web of Science ®Google Scholar
• AMON U, GIBBS BF, BUSS G et al.: In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. billamm. Res. (2000) 49:112–116.
   PubMed Web of Science ®Google Scholar
• FUGNER A, MEISSNER C: Accumulation of granulocytes in the lung and skin of guinea pigs. Inhibition by the anti-H1 antiallergic agent epinastine. Arzneimittelforschung (1994) 44:1338–1342.
   Google Scholar
• SUGIMOTO Y, KAWAMOTO E, CHEN Z et al.: A new model of allergic rhinitis in rats by topical sensitization and evaluation of H(1)-receptor antagonists. Immurropharmacology (2000) 48:1–7.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO W, HIROI T, SAKAI K et al.: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res. Commun. Mol. Pathol Pharmacol (1997) 98:273–292.
   PubMed Web of Science ®Google Scholar
• YANAI K, RYU JH, WATANABE T et al: Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods Paid Esp. Chi]. Pharmacol (1995) 17:64–69.
   Google Scholar
• OHMURA T, CHACHIN M, TARUI S et al.: Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys. Eur. j Pharmacol (1999) 378:169–175.
   PubMed Web of Science ®Google Scholar
• OGISO T, KASUTANI M, TANAKA H et al.: Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. Biol. Pharm. Bull. (2001) 24:790–794.
   PubMed Web of Science ®Google Scholar
• HURST M, SPENCER CM: Ebastine: an update of its use in allergic disorders. Drugs (2000) 59:981–1006.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, SIMONS KJ: Clinical pharmacology of new histamine H1 receptor antagonists. Chi]. Pharmacokinet. (1999) 36:329–352.
   PubMed Web of Science ®Google Scholar
• JANSEN B, GRASELLI U, DALLINGER S et al.: Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. Eur. Chi]. Pharmacol (2000) 55:837–841.
   PubMed Web of Science ®Google Scholar
• SHARIF NA, SU SX, YANNI JM: Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul. Pharmacol (1994) 10:653–664.
   PubMedGoogle Scholar
• YANNI JM, WEIMER LK, SHARIF NA et al.: Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophthalmol. (1999) 117:643–647
   PubMed Web of Science ®Google Scholar
• ANDOH T, KURAISHI Y: Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice. Eur. Pharmacol. (2000) 406:149–152.
   PubMed Web of Science ®Google Scholar
• VERIN P, EASTY DL, SECCHI A et al.: Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am. j. Ophthalmol (2001) 131:691–698.
   Google Scholar
• HERRANZ U, RUSCA A, ASSANDRI A: Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Int. j. Chi]. Pharmacol Ther. (2001) 39:102–109.
   PubMed Web of Science ®Google Scholar
• JOUKHADAR C, HERRANZ U, PERNERSTORFER T et al: Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment. Eur. j Cliii. Pharmacol (2001) 56:905–910.
   PubMed Web of Science ®Google Scholar